新一代治疗糖尿病药物对阿尔茨海默病的干预机制及进展

Mechanism and progress of new drugs for treatment of diabetes in intervention of Alzheimer’s disease

摘要:

2型糖尿病(T2DM)与阿尔茨海默病(AD)在病因及病理生理方面具有相似性,近年研究表明胰高血糖素样肽1 (GLP-1)、二肽基肽酶4(DPP-4)抑制剂、钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂等新型降糖药有中枢作用,为此学者们提出了治疗AD 的新策略,即应用控制T2DM的新型药物干预AD。本文综述了AD病理生理特点,AD和T2DM的相关性以及GLP-1、DPP-4抑制剂、SGLT2抑制剂治疗AD 的相关研究进展。

Abstract:

Type 2 diabetes mellitus (T2DM) is proven to have some similarities in etiology and pathophysiology with Alzheimer’s disease (AD). In recent years, evidence also has suggested that some new drugs for diabetes, such as glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitor, have some effects on the central nervous system. These findings provide new strategy for AD treatment, that is, using these diabetes drugs for intervention of AD. In this paper, we reviewed the pathophysiological characteristics of AD, the correlation between AD and T2DM, and the application of GLP-1, DPP-4 inhibitor and SGLT2 inhibitor in the intervention of AD.